Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes
Recruiting · NCT06699979 · Observational (researchers observe without assigning treatment)
View the official record on ClinicalTrials.gov →What this trial is about
The goal of this observational study is to investigate the multi-omics characterization early-stage lung cancer exhibiting distinct phenotypes including lung cancer associated with cystic airspaces, multiple primary lung cancers, and so on. The main questions it aims to answer are: * What are the differences in pathogenesis of non-small cell lung cancer with different phenotypes explored by multi-omics? * Whether differential genes lead to potential prognostic models and therapeutic targets? Participants will be followed up after surgery to answer prognosis: whether they have recurred, and the time to recurrence.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Male or female patients:18-75 years old;
- ECOG score:0-1;
- Histopathologically confirmed TNM stage I-II NSCLC;
- Considered multiple or solitary primary lung cancer by clinical criteria (Martini-Melamed criteria and ACCP criteria);
- Good compliance, family members agree to cooperate to receive survival follow-up;
- Understand and voluntarily sign the informed consent.
Exclusion criteria
- A history of previous or co-existing malignant tumors;
- Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment;
- Refusal to participate in the study.
- Cohort 2: Multi-omics study of lung cancer associated with cystic airspaces
- Inclusion criteria:
- Male or female patients:18-75 years old;
- ECOG score:0-1;
- Histopathologically confirmed TNM stage I-II NSCLC;
- CT findings show solitary or multiple nodules with cystic airspaces.
- Exclusion criteria:
- A history of previous or co-existing malignant tumors;
- Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment;
- Refusal to participate in the study.
Where it is running
1 location listed.
- The Second Xiangya Hospital of Central South University - Changsha, Hunan, China